Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 89

Showing 26-50 of 89 citing articles:

An updated meta-analysis of Chinese herbal medicine for the prevention of COVID-19 based on Western-Eastern medicine
Siying Hu, Dan Luo, Qikui Zhu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2
Rohitas Deshmukh, Ranjit K. Harwansh, Akash Garg, et al.
Current Genomics (2024) Vol. 25, Iss. 2, pp. 69-87
Open Access | Times Cited: 3
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials
Ilias Ι. Siempos, André C. Kalil, Drifa Belhadi, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102472-102472
Open Access | Times Cited: 3
Current management of SARS‐CoV‐2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey
Alessandro Visentin, E. Pickavance, Rafael San Juan, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 2
Closed Access | Times Cited: 3
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde S Ørbo, K. H. Bjørlykke, Joseph Sexton, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003545-e003545
Open Access | Times Cited: 3
Hybrid Immunity Provides the Best COVID-19 Humoral Response in Immunocompromised Patients with or without SARS-CoV-2 Infection History
Paulina Nazaruk, Ignacy Tkaczyk, Marta Monticolo, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1380-1380
Open Access | Times Cited: 8
What do we know about covid in immunocompromised people?
Katharine Lang
BMJ (2023), pp. p1612-p1612
Open Access | Times Cited: 8
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
Stephen Boulton, Joanna Poutou, Rida Gill, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101110-101110
Open Access | Times Cited: 7
Anti-SARS-CoV2 serological profile and associated factors in adults living with HIV followed at Departmental and Teaching Hospital of Borgou in 2022.
Attinsounon Cossi Angelo, Dovonou Comlan Albert, Alidjinou Kazali, et al.
Journal of Infectiology (2024) Vol. 6, Iss. 2, pp. 5-10
Open Access | Times Cited: 2
Racial and Ethnic Disparities in COVID-19 Treatments in the United States
Essy Mozaffari, Aastha Chandak, Alpesh Amin, et al.
Journal of Racial and Ethnic Health Disparities (2024)
Open Access | Times Cited: 2
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis
Sonphet Chirasuthat, Yanisa Ratanapokasatit, Kunlawat Thadanipon, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40009-adv40009
Open Access | Times Cited: 2
Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study
Irit Nachtigall, Stefan Kwast, Sven Hohenstein, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 634-634
Open Access | Times Cited: 2
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
José Luís Piñana, Lourdes Vázquez, Inmaculada Heras, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
The Association of Physical Distancing Behaviors to Avoid COVID-19 with Health-Related Quality of Life in Immunocompromised and Non-Immunocompromised Individuals: The Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study (Preprint)
Paul Williams, Timothy A. Herring, Renata Yokota, et al.
JMIR Research Protocols (2024) Vol. 13, pp. e52643-e52643
Open Access | Times Cited: 2
Association Between Pneumococcal Vaccination Uptake and Loneliness Among Regular Patients in Rural Community Hospitals: A Cross-Sectional Study
Ryuichi Ohta, Toshihiro Yakabe, Hiroshi Adachi, et al.
Cureus (2024)
Open Access | Times Cited: 2
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection
Carolin M. Lieber, Hae-Ji Kang, Elizabeth B. Sobolik, et al.
Journal of Virology (2024) Vol. 98, Iss. 9
Closed Access | Times Cited: 2
Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza
Ting-Hui Liu, Po‐Yu Huang, Jheng‐Yan Wu, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Employee investigation and contact tracing program in a pediatric cancer hospital to mitigate the spread of COVID-19 among the workforce, patients, and caregivers
Diego R. Hijano, Sandra R. Dennis, James M. Hoffman, et al.
Frontiers in Public Health (2024) Vol. 11
Open Access | Times Cited: 2
An eDElphi STudy to defINe and risk-stratify ImmunosupprESsion: Protocol for the DESTINIES Study (Preprint)
Meredith Leston, José Ordóñez-Mena, Mark Joy, et al.
JMIR Research Protocols (2024) Vol. 13, pp. e56271-e56271
Open Access | Times Cited: 2
Identification of Dual Inhibitors Targeting Main Protease (Mpro) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 5, pp. 602-609
Closed Access | Times Cited: 1
Impact of Respiratory Viral Infections in Transplant Recipients
Hannah Bahakel, Alpana Waghmare, Rebecca Pellet Madan
Journal of the Pediatric Infectious Diseases Society (2024) Vol. 13, Iss. Supplement_1, pp. S39-S48
Open Access | Times Cited: 1
Documento de posición sobre vacunación COVID-19 en pacientes inmunosuprimidos en todas las etapas de la vida
Florencia Cahn, Laura Barcán, Pablo Bonvehí, et al.
Actualizaciones en Sida e Infectología (2024)
Open Access | Times Cited: 1
Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups
Samah Hayek, Joseph Levy, Galit Shaham, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 6, pp. 1379-1389
Open Access | Times Cited: 1
SARS-CoV-2 Humoral and Cellular Immune Responses in HIV-Positive Patients
Simona Ruță, Corneliu Petru Popescu, Lilia Matei, et al.
(2024)
Open Access | Times Cited: 1
Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection
Carolin M. Lieber, Hae-Ji Kang, Elizabeth B. Sobolik, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1

Scroll to top